Probity Advisors, Inc. Gilead Sciences, Inc. Transaction History
Probity Advisors, Inc.
- $546 Million
- Q2 2025
A detailed history of Probity Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Probity Advisors, Inc. holds 13,516 shares of GILD stock, worth $1.52 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
13,516
Previous 13,906
2.8%
Holding current value
$1.52 Million
Previous $1.56 Million
3.85%
% of portfolio
0.27%
Previous 0.31%
Shares
18 transactions
Others Institutions Holding GILD
# of Institutions
2,292Shares Held
1BCall Options Held
9.59MPut Options Held
10M-
Black Rock Inc. New York, NY121MShares$13.6 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$13.2 Billion0.25% of portfolio
-
State Street Corp Boston, MA59.5MShares$6.69 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.6MShares$6.14 Billion1.39% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$6.02 Billion1.01% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $141B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...